FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198494085> ?p ?o ?g. }

• W3198494085 abstract "Background: Historically, high rates of actionable driver mutations have been reported in never-smokers with lung adenocarcinoma (LUAD); however, in the era of modern, comprehensive cancer mutation sequencing, this relationship necessitates a more detailed analysis.Methods: All Mount Sinai patients between 01/01/2015 and 6/01/2020 with a diagnosis of LUAD of any stage with known smoking status who received genomic testing were included. Most patients were analyzed using the Sema4 hotspot panel or the OCAv3 NGS panel conducted at Sema4. Patients were considered fully genotyped if they were comprehensively analyzed for alterations in EGFR, KRAS, MET, ALK, RET, ROS1, BRAF, NTRK1-3, and ERBB2, otherwise they were considered partially genotyped.Findings236 never-smokers and 671 smokers met the above criteria. Of the never-smokers, 201 (85%) had a driver mutation with 175 (74%) considered actionable. Among smokers, 436 (65%) had an identified driver mutation with 268 (40%) actionable (p<0.0001). When comprehensively sequenced, 95% (70/74) of never-smokers had a driver mutation with 80% (59/74) actionable; whereas, for smokers, 73% (131/180) had a driver with only 44% (79/180) actionable (p<0.0001). Within mutations groups, EGFR G719X and KRAS G12Cs were more common to smokers. For stage IV patients harboring EGFR-mutant tumors treated with EGFR-directed therapies, never-smokers had significantly improved overall survival compared to smokers (HR=3.50; p=0.0066). In multivariable analysis, Asian ancestry and female gender remained significant predictors of 1) overall survival i n stage IV patients and 2) likelihood of harboring an actionable driver mutation.Interpretation: Comprehensive NGS revealed driver alterations in 95% of never-smokers, with the majority having an associated therapy available. All efforts should be exhausted to identify or rule out the presence of an actionable driver mutation in LUAD patients requiring systemic treatment. Funding: Center for Thoracic Oncology Seed fundingDeclaration of Interests: MIK, KLA, XZ, SG, MF, MR, HA, FMH, WKO, SN, EES, RC are employed by Sema4 and some declare ownership of stock options of Sema4. No other competing interests to declare. PCM has received honoraria from Guardant Health and Amgen. FRH served on advisory boards for Bristol-Myers Squibb, Merck, Novartis, Genentech, AstraZeneca/Daiichi, Sanofi/Regeneron, OncoCyte, Amgen. Patent: “EGFR copy number and Protein Expression as Predictive Biomarker for EGFR directed Therapy” Co-inventor. Patent through University of Colorado. (no royalties) Ethics Approval Statement: Study permission was granted by the Mount Sinai IRB. The procedures followed in this study were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration." @default.
• W3198494085 created "2021-09-13" @default.
• W3198494085 creator A5010265482 @default.
• W3198494085 creator A5021691020 @default.
• W3198494085 creator A5029654362 @default.
• W3198494085 creator A5030981561 @default.
• W3198494085 creator A5038916228 @default.
• W3198494085 creator A5046410639 @default.
• W3198494085 creator A5049311354 @default.
• W3198494085 creator A5063514061 @default.
• W3198494085 creator A5067298527 @default.
• W3198494085 creator A5071851332 @default.
• W3198494085 creator A5071946434 @default.
• W3198494085 creator A5078027978 @default.
• W3198494085 creator A5089011631 @default.
• W3198494085 creator A5089749766 @default.
• W3198494085 date "2021-01-01" @default.
• W3198494085 modified "2023-09-27" @default.
• W3198494085 title "Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers with Lung Adenocarcinoma" @default.
• W3198494085 cites W1509970002 @default.
• W3198494085 cites W1533283182 @default.
• W3198494085 cites W1967728016 @default.
• W3198494085 cites W1977415173 @default.
• W3198494085 cites W1978023782 @default.
• W3198494085 cites W1993432948 @default.
• W3198494085 cites W1999462166 @default.
• W3198494085 cites W2040299716 @default.
• W3198494085 cites W2041992600 @default.
• W3198494085 cites W2075047925 @default.
• W3198494085 cites W2075514629 @default.
• W3198494085 cites W2076334024 @default.
• W3198494085 cites W2077582166 @default.
• W3198494085 cites W2086046963 @default.
• W3198494085 cites W2132542518 @default.
• W3198494085 cites W2135911067 @default.
• W3198494085 cites W2180481128 @default.
• W3198494085 cites W2222708997 @default.
• W3198494085 cites W2228221433 @default.
• W3198494085 cites W2567342709 @default.
• W3198494085 cites W2603411876 @default.
• W3198494085 cites W2730090387 @default.
• W3198494085 cites W2809937927 @default.
• W3198494085 cites W2960479648 @default.
• W3198494085 cites W3022801864 @default.
• W3198494085 cites W3029683774 @default.
• W3198494085 cites W3087229737 @default.
• W3198494085 cites W3109420156 @default.
• W3198494085 doi "https://doi.org/10.2139/ssrn.3914657" @default.
• W3198494085 hasPublicationYear "2021" @default.
• W3198494085 type Work @default.
• W3198494085 sameAs 3198494085 @default.
• W3198494085 citedByCount "0" @default.
• W3198494085 crossrefType "journal-article" @default.
• W3198494085 hasAuthorship W3198494085A5010265482 @default.
• W3198494085 hasAuthorship W3198494085A5021691020 @default.
• W3198494085 hasAuthorship W3198494085A5029654362 @default.
• W3198494085 hasAuthorship W3198494085A5030981561 @default.
• W3198494085 hasAuthorship W3198494085A5038916228 @default.
• W3198494085 hasAuthorship W3198494085A5046410639 @default.
• W3198494085 hasAuthorship W3198494085A5049311354 @default.
• W3198494085 hasAuthorship W3198494085A5063514061 @default.
• W3198494085 hasAuthorship W3198494085A5067298527 @default.
• W3198494085 hasAuthorship W3198494085A5071851332 @default.
• W3198494085 hasAuthorship W3198494085A5071946434 @default.
• W3198494085 hasAuthorship W3198494085A5078027978 @default.
• W3198494085 hasAuthorship W3198494085A5089011631 @default.
• W3198494085 hasAuthorship W3198494085A5089749766 @default.
• W3198494085 hasConcept C104317684 @default.
• W3198494085 hasConcept C121608353 @default.
• W3198494085 hasConcept C143998085 @default.
• W3198494085 hasConcept C2776256026 @default.
• W3198494085 hasConcept C2781182431 @default.
• W3198494085 hasConcept C502942594 @default.
• W3198494085 hasConcept C51679486 @default.
• W3198494085 hasConcept C54355233 @default.
• W3198494085 hasConcept C70721500 @default.
• W3198494085 hasConcept C71924100 @default.
• W3198494085 hasConcept C86803240 @default.
• W3198494085 hasConceptScore W3198494085C104317684 @default.
• W3198494085 hasConceptScore W3198494085C121608353 @default.
• W3198494085 hasConceptScore W3198494085C143998085 @default.
• W3198494085 hasConceptScore W3198494085C2776256026 @default.
• W3198494085 hasConceptScore W3198494085C2781182431 @default.
• W3198494085 hasConceptScore W3198494085C502942594 @default.
• W3198494085 hasConceptScore W3198494085C51679486 @default.
• W3198494085 hasConceptScore W3198494085C54355233 @default.
• W3198494085 hasConceptScore W3198494085C70721500 @default.
• W3198494085 hasConceptScore W3198494085C71924100 @default.
• W3198494085 hasConceptScore W3198494085C86803240 @default.
• W3198494085 hasLocation W31984940851 @default.
• W3198494085 hasOpenAccess W3198494085 @default.
• W3198494085 hasPrimaryLocation W31984940851 @default.
• W3198494085 hasRelatedWork W1602357875 @default.
• W3198494085 hasRelatedWork W2002128513 @default.
• W3198494085 hasRelatedWork W2390152934 @default.
• W3198494085 hasRelatedWork W2403361534 @default.
• W3198494085 hasRelatedWork W2472792300 @default.
• W3198494085 hasRelatedWork W2743740828 @default.
• W3198494085 hasRelatedWork W2888534976 @default.
• W3198494085 hasRelatedWork W2908922480 @default.

• next